AI-Driven Aptamer Design Service
Are you currently facing long drug development cycles, the failure of traditional SELEX to find high-affinity binders, and the need to drug challenging or "undruggable" protein targets? Our AI-Driven Aptamer Design Service helps you accelerate lead generation with high confidence and reduce early-stage failure rates.
Accelerate Your Therapeutic Discovery Pipeline with our Service!
Introduction of AI-Driven Aptamer Design
The field of molecular recognition has been transformed by aptamers—synthetic oligonucleotides (DNA or RNA) that fold into specific 3D shapes to bind targets with high affinity. Aptamers offer key advantages over traditional antibodies, including superior stability, lower cost of manufacturing, and non-immunogenicity. However, the de novo design of high-performing aptamers has historically been limited by the laborious, low-yield process of SELEX. AI models can efficiently navigate the astronomical sequence space, predicting candidates with structural viability and functional potential. Creative Biolabs' approach is built on this foundation, but goes further: we integrate AI speed with rigorous validation to ensure the delivered leads translate directly to therapeutic success, overcoming the common industry trade-off between sequence novelty and functional reliability.
What Are Services?
Creative Biolabs' AI-Driven Aptamer Design Service provides comprehensive lead generation for high-affinity oligonucleotides tailored to your specific molecular target. Application Scenarios:
- Therapeutics: Designing novel binders for difficult protein targets for use in drug delivery or direct inhibition.
- Diagnostics/Biosensors: Generating high-specificity aptamers for biomarker capture in advanced molecular assays or Point-of-Care (PoC) systems.
- Targeted Delivery: Engineering ligands for use in LNP or exosome formulations to ensure tissue- or cell-specific cargo delivery.
Why Choose Us?
We solve the fundamental problem facing R&D teams: the Confidence Gap between predicted performance and confirmed functional results.
| Pain Points | Benefit Created by Creative Biolabs |
|---|---|
| Low Success Rate | Guaranteed fine Success Rate for high affinity (Confirmed by SPR). |
| Long Timelines | Reduced Time-to-Lead (Rapid AI screening and validated candidates). |
| High Development Risk | De-Risked Pipeline Progression (Providing leads with confirmed kinetics and stability). |
Fig.1 Computational design of aptamers.1
How Creative Biolabs' AI-Driven Aptamer Design Service Can Assist Your Project
Creative Biolabs provides validated aptamer leads, not just computationally predicted sequences. We deliver performance certainty through our integrated, multi-stage platform.
Workflow
- Target Information
- Binding Requirements
- Application Context
Discover Our Offerings - Book a Consultation!
Key Benefits
Creative Biolabs is engineered to deliver high-confidence molecular leads, turning the uncertainty of AI prediction into the certainty of functional performance.
- Accelerated Time-to-Lead: By reducing the massive search space in silico and eliminating unnecessary wet-lab iteration, we highly reduce the total time required for lead identification compared to traditional SELEX or unvalidated AI screening.
- Rational Multi-Attribute Design: Our AI does not just design for affinity; it designs for therapeutic function. Sequences are rationally optimized in one step for binding affinity, structural stability, and manufacturability.
- Expert Data Analysis and Rescue: Leveraging our AI and biophysics expertise, we can also analyze complex, existing SELEX Next-Generation Sequencing (NGS) data to rescue high-performance aptamers that were missed by conventional bioinformatics tools.
Experience the Edge with Creative Biolabs - Request a Quote Now!
Deliverables
- Final Lead Aptamer Sequences: 1-3 fully characterized and chemically optimized oligonucleotide sequences.
- Biophysical Validation Report: Detailed report including all raw and analyzed data, structural confirmation.
- Molecular Modeling & Optimization Report: Documentation of the AI-driven design pipeline, predicted folding structures, and justification for all chemical modifications applied for stability enhancement.
- Synthesis and Purity Certificate: Confirmation of sequence integrity and purity.
- Functional Assay Data: Results from initial binding assays used to confirm initial function.
Frequently Asked Questions
Q1: My target protein is very challenging. Can your platform handle it?
A: Yes, our platform is specifically designed for challenging targets. The Generative AI bypasses the need for in vivo immunization (a limitation for traditional antibodies) and the biases of physical selection (SELEX). It uses computational modeling to design binders for epitopes that are structurally viable but non-immunogenic, allowing us to pursue targets that are considered "undruggable" by conventional methods.
Q2: We have existing SELEX data that failed to yield a strong candidate. Can you salvage it?
A: Absolutely. We offer a specialized Data Rescue Service using our AI platform. We apply our proprietary deep learning models to your existing Next-Generation Sequencing (NGS) data to analyze sequence-function relationships. This often allows us to identify and optimize high-performing aptamers that were present in the pool but missed by conventional bioinformatics thresholds.
Q3: How does your service ensure the aptamers will be stable for therapeutic use?
A: Stability is a key attribute our AI co-optimizes for during the design phase. Furthermore, the Lead Optimization stage specifically involves incorporating stabilizing chemical modifications guided by both our AI predictions and wet-lab stability assays.
Contact Us
Creative Biolabs' AI-Driven Aptamer Design Service represents the future of molecular therapeutics. We resolve the critical industry trade-off by integrating the speed and novelty of Generative AI with the certainty of Quantitative Biophysical Validation. We deliver therapeutically viable aptamer leads, ensuring rapid and reliable progression through your discovery pipeline. To learn more about how Creative Biolabs can transform your therapeutic or diagnostic project, please reach out to our team of experts.
Reference
- Lee, Su Jin, et al. "Design and prediction of aptamers assisted by in silico methods." Biomedicines 11.2 (2023): 356. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/biomedicines11020356